OUR TECHNOLOGY
The company's innovative technology involves a series of small molecules that were jointly developed by the co-founder of the company, Prof. Bernard Lerer from Hadassah Medical Center and Prof. Govindasamy Mugesh from Indian Institute of Science.
Those Molecules specifically target the DIO3 enzyme which is highly expressed in various aggressive cancers, including high grade serous ovarian cancer (HGSOC). DIO3 is an attractive target for inhibition since it is responsible for breaking down thyroid hormones, including the biological hormone T3. Because T3 has anti-cancer functions, many tumors express this enzyme, thereby facilitating the division of cancer cells. Our team is the first to generate a series of novel small molecules for DIO3 inhibition, and we are proud to have been granted patent protection in the US and Europe (EP3119768B1; US10435365B2).
Here are some of our key findings:
-
We have established that ovarian cancer is DIO3-dependent in both cells and mice models.
-
Using the 'best hit' DIO3 inhibitors, we have achieved high efficacy in both ovarian cancer cells and mice models.
-
We have confirmed a high safety profile through toxicology experiments.
With these exciting results, we are confident that our technology has the potential to make a significant impact in the fight against cancer
